- Investing Ideas
- /
- Brazilian Pharmaceuticals & Biotech Potentially Undervalued Companies
Brazilian Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED May 16, 2024
Companies with a Value score of at least 3, ordered by Value score
26 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
OFSA3 | R$21.42 | -0.4% | -11.9% | R$1.2b | R$23.50 | PS1.2x | E96.6% | 3.1% | ||
G1SK34 | UK£46.82 | 1.9% | 33.0% | UK£72.7b | UK£53.35 | PE16.2x | E12.2% | 3.3% | ||
HYPE3 | R$30.28 | 0.8% | -23.2% | R$19.2b | R$40.47 | PE11.3x | E13.2% | 4.1% | ||
BMYB34 | US$225.25 | -2.0% | -31.7% | US$89.4b | US$271.64 | PS2x | E43.8% | 5.4% | ||
GILD34 | US$169.93 | 1.9% | -11.7% | US$83.5b | US$207.62 | PE174.3x | E36.5% | 4.5% | ||
BIIB34 | US$171.36 | 0% | -31.9% | US$34.3b | US$208.21 | PE29.4x | E17.8% | n/a | ||
P1RG34 | US$153.30 | 0% | n/a | US$4.1b | US$201.17 | PE5129.1x | E49.3% | 3.7% | ||
U2TH34 | US$56.21 | 0% | n/a | US$12.1b | US$60.45 | PE11.5x | E6.7% | n/a | ||
D2NL34 | US$20.23 | 0% | n/a | US$2.9b | US$38.65 | PS9.8x | E9.8% | n/a | ||
T1EV34 | US$41.50 | -1.7% | 107.7% | US$18.5b | US$44.14 | PS1.2x | E40.4% | 0% | ||
REGN34 | US$83.20 | -0.8% | 31.4% | US$104.4b | US$89.33 | PE27.1x | E12.5% | n/a | ||
E2XA34 | US$27.42 | -23.2% | -30.5% | US$9.8b | US$45.70 | PS3.8x | E65.9% | n/a | ||
I1NC34 | US$136.64 | 0% | -16.8% | US$12.8b | US$176.21 | PE17.1x | E17.8% | n/a | ||
PFIZ34 | US$37.12 | 2.9% | -18.9% | US$163.9b | US$40.99 | PS3x | E28.9% | 5.8% | ||
B2RK34 | US$38.48 | -5.7% | 5.9% | US$11.3b | US$43.50 | PE27.4x | E6.8% | 0.3% | ||
B1GN34 | US$34.94 | 3.6% | -23.8% | US$17.9b | US$54.55 | PS6.5x | E60.6% | n/a | ||
ABBV34 | US$52.50 | 1.1% | 15.5% | US$290.2b | US$57.99 | PE48.8x | E23.3% | 3.8% | ||
BLAU3 | R$10.67 | -1.2% | -49.0% | R$1.9b | R$13.57 | PE8x | E10.6% | 7.0% | ||
JNJB34 | US$52.64 | 2.0% | -0.4% | US$371.3b | US$59.12 | PE21.7x | E6.9% | 3.2% | ||
A1LN34 | US$37.68 | -3.2% | -19.3% | US$19.1b | US$54.91 | PS9.5x | E64.2% | n/a | ||
M1RN34 | US$34.05 | 12.1% | 8.1% | US$50.8b | US$35.55 | PS9.9x | E68.8% | n/a | ||
E2XE34 | US$60.25 | 0% | n/a | US$6.2b | US$75.46 | PE30.2x | E23.8% | n/a | ||
M2RT34 | US$19.46 | 0.6% | 29.0% | US$4.1b | US$20.22 | PS107.8x | E29.9% | n/a | ||
J2AZ34 | US$38.72 | -0.6% | n/a | US$6.9b | US$63.78 | PE21.1x | E18.5% | n/a |